CVKD fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
CVKD does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company